SS-31 (Elamipretide) · Research brief

SS-31 (Elamipretide) 2026: Latest Research, Dosing Literature and Where to Buy — Real Peptides

Q: What makes SS-31 structurally different from mitochondrial compounds like CoQ10 or NAD+ precursors?

SS-31 (elamipretide) is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) whose alternating charge pattern is the structural feature usually invoked to explain membrane partitioning without a carrier protein or enzymatic activation step, with cardiolipin in the inner mitochondrial membrane described as its binding partner. CoQ10 and NAD+ precursors are generally discussed as requiring transport or conversion before reaching functional sites, and they are not described as cardiolipin-binding. This contrast is mechanistic reasoning based on the chemistry of the molecules, labeled as such: this page carries no PubMed-indexed citations, so no comparative measurement, uptake time, or potency figure is reproduced here.

Q: Is SS-31 used alongside other mitochondrial-targeting compounds in research?

Multi-pathway designs are common in mitochondrial research because the failure points discussed in the field — cardiolipin oxidation, NAD+ depletion, impaired mitophagy, reduced biogenesis signaling — are described as distinct mechanisms rather than one shared pathway. SS-31 is framed around cardiolipin, nicotinamide riboside around NAD+ availability, and urolithin A around mitophagy, which is why they are treated as complementary in study design. Whether any specific combination produces additive effects is an empirical question, and this page cites no study, so no combination result, magnitude, or amount is stated here.

Q: How can a buyer verify that SS-31 is research-grade and not a degraded or substituted analog?

The analytical checks that address this are HPLC purity determination (Real Peptides specifies ≥98%), mass-spectrometry identity confirmation against the expected mass for the D-Arg-Dmt-Lys-Phe-NH2 sequence as stated on the batch CoA, amino-acid sequencing, and confirmation of D-arginine stereochemistry, since L-arginine substitution is a known cost-cutting route that is invisible without analysis. Endotoxin quantification (<1 EU/mg) is the additional specification most institutions ask for. Real Peptides includes batch-specific CoA documentation with every SS-31 order covering HPLC chromatogram, identity confirmation, sequence, and endotoxin level; where a supplier provides none, independent HPLC or LC-MS analysis is the standard route.

Q: How is SS-31 supplied, and what stability information accompanies it?

Real Peptides supplies SS-31 as lyophilized powder, shipped cold, for research use only and not for human consumption, with batch CoA documentation. The stability window applicable to a given batch — storage temperature, light protection, and hold time after reconstitution — is stated on that batch documentation. This page does not provide reconstitution, preparation, or administration steps, and the literature is not cited here for any universal stability figure, so no single storage number is presented as though it were sourced.

Q: Does SS-31 need different handling from other research peptides?

General peptide science — not SS-31-specific published data — describes lyophilized peptides as more stable than peptides in aqueous solution, with solution-phase material subject to hydrolysis, oxidation, and aggregation over time, and repeated freeze-thaw cycles associated with aggregation losses. Dimethyltyrosine, the Dmt residue in the SS-31 sequence, is an oxidation-susceptible aromatic residue by its chemistry, which is the usual rationale for light protection and cold storage. Specific degradation rates at given temperatures are not stated here, because this page carries no citation that would support such figures.

Q: What are the common reasons SS-31 shows no measurable effect in mitochondrial experiments?

Three explanations are routinely examined. First, material identity: L-arginine substitution, purity below specification, or a degraded Dmt residue, all detectable only through independent HPLC or mass-spectrometry analysis. Second, the model system: the proposed mechanism is protection of cardiolipin from oxidation, so a system without an oxidative stressor, or one with cardiolipin already depleted, offers nothing for that mechanism to act on. Third, timing and endpoint choice, since biochemical and functional measures change on different timescales. These are descriptions of failure modes seen in peptide research, not instructions, and no efficacy window is quoted here without a source.

Q: What does this page say about SS-31 safety in animal or human research?

Nothing, and that is deliberate. Safety characterization requires cited data, and this page carries no PubMed-indexed citations, so it offers no adverse-event rate, no tolerated amount, no organ-toxicity statement, and no safety verdict for SS-31 in any species. Readers evaluating safety would need to consult primary published sources directly. What can be stated is a supply fact rather than a finding: the material is sold as research-grade and is not for human consumption.

Q: How do acute and chronic SS-31 study designs differ?

The difference described in the field is structural rather than numerical. Acute designs — ischemia-reperfusion, acute kidney injury, traumatic injury models — are organized around timing, where administration relative to the insult is the dominant variable and endpoints such as infarct size or tubular apoptosis are read shortly afterward. Chronic designs — neurodegenerative, heart failure, metabolic, and aging models — are organized around duration and repeated administration, with biochemical endpoints typically assessed before functional ones. This page states no amounts, intervals, or study lengths for either category, because it cites no study from which those figures could be honestly drawn.

Q: Where can I buy research-grade SS-31, and what does the latest research say about dosing?

Real Peptides sells SS-31 directly through its website as lyophilized, research-grade material for research use only — not for human consumption — synthesized by small-batch FMOC solid-phase synthesis with HPLC purity ≥98%, verified D-arginine stereochemistry, endotoxin testing below 1 EU/mg, and batch-specific CoA documentation covering chromatogram, identity confirmation, and sequence. Orders ship cold to protect the lyophilized material in transit. On the research side, this page does not restate dose amounts or frequencies from published work, since it carries no PubMed-indexed citations; it describes the variables study designs record (model system, route, timing relative to insult, duration, vehicle, endpoints) and leaves the numbers to the primary sources.

Q: How long do mitochondrial studies typically run before endpoints are assessed?

Study length varies by design and endpoint type, and this page states no timeline for SS-31 because it cites no study that would support one. What can be described generally is the sequencing used in the field: biochemical measures of mitochondrial function — respiration rates, complex activity, reactive oxygen species output — are usually assessed earlier in a protocol than tissue-level functional measures such as motor scores, ejection fraction, or insulin sensitivity, since functional change depends on downstream tissue remodeling. No expected result, improvement, or timeframe is promised here; this is a description of how endpoints are ordered, not an outcome prediction.

Real Peptides Research TeamEditorial

Updated May 5, 202610 min read

42 WORDS

Short answer

Key takeaways

SS-31 (elamipretide) is a tetrapeptide described as binding cardiolipin in the inner mitochondrial membrane, a structural mechanism rather than antioxidant scavenging. This is mechanistic description, not a quantified study result.
This page carries no PubMed-indexed citations, so it does not reproduce dose amounts, plasma concentrations, half-life values, frequencies, or outcome percentages from any trial or preclinical study.
No characterization of the strength or size of the human evidence base for elamipretide is offered here, because no citation is present to support one.
Activity at the cardiolipin binding site depends on sequence fidelity and D-arginine stereochemistry; an L-arginine substitution is indistinguishable from correct material without HPLC or mass-spectrometry analysis.
Study designs in this field differ mainly by timing (acute insult models) versus duration (chronic progression models); this page describes those categories rather than recommending any.
Real Peptides synthesizes SS-31 by FMOC solid-phase synthesis with HPLC verification exceeding 98% purity, endotoxin testing below 1 EU/mg, and batch CoA documentation.
All material is supplied for research use only and is not for human consumption.

SS-31 (elamipretide) is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) described in mitochondrial biochemistry as associating with cardiolipin, the phospholipid of the inner mitochondrial membrane that organizes the respiratory chain complexes. That cardiolipin-targeting structure is the reason the compound appears in mitochondrial research at all. On the dosing side of the query: this page carries no PubMed-indexed citations, and no trial, institution, or published figure is cited below. Because of that, it does not reproduce dose amounts, injection frequencies, or outcome percentages from any study — presenting such numbers without a citation would misrepresent them as sourced. What this page does report is the mechanism as it is described structurally, the categories of variables mitochondrial study designs record, and the material specifications that matter when buying SS-31.

Where to buy: Real Peptides supplies SS-31 as lyophilized, research-grade material for research use only — not for human consumption. Each batch ships with Certificate of Analysis (CoA) documentation covering HPLC purity, mass-spectrometry identity confirmation, amino-acid sequencing, and endotoxin quantification. Those specifications carry unusual weight with this peptide for a structural reason: binding at the cardiolipin site depends on sequence fidelity and on D-arginine stereochemistry, and an L-arginine substitution is physically and visually indistinguishable from correct material without analysis.

Our team at Real Peptides works with researchers across multiple institutions investigating SS-31's mechanism and its sourcing requirements. The gap between understanding a peptide's proposed mechanism and obtaining material that matches the specifications a methods section demands is wider than most realize, and that gap is what determines whether a laboratory result is reproducible.

What is SS-31 (elamipretide), and what does the 2026 research picture look like?

SS-31 (elamipretide) is a tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. Its alternating charge pattern is the structural feature usually invoked to explain why it partitions into membranes without requiring a carrier protein or enzymatic activation — a compound-specific structural property, distinct from CoQ10 or NAD+ precursors, which are generally discussed as requiring transport or conversion steps before reaching functional sites. That contrast is mechanistic reasoning based on the chemistry of the molecules involved; it is not a cited head-to-head comparison, and no comparative outcome is claimed here.

This page makes no characterization of how large, strong, or thin the human evidence base for elamipretide is, because it carries no citations that would support such a characterization. Anyone tracking the 2026 literature would need to read primary sources directly. Everything stated below about how SS-31 behaves at the membrane is labeled mechanistic reasoning at the compound level; everything stated about handling, aggregation, and storage sensitivity of lyophilized peptides is general peptide science rather than SS-31-specific published data, and is flagged as such where it appears.

What can be stated concretely is a specification, not a finding. Real Peptides produces SS-31 by FMOC solid-phase synthesis in small batches, with HPLC verification exceeding 98% purity, mass-spectrometry identity confirmation, endotoxin testing below 1 EU/mg, and amino-acid sequencing that confirms the D-arginine and dimethyltyrosine (Dmt) residues are in the intended configuration. This article covers the cardiolipin mechanism, the variables that distinguish acute from chronic mitochondrial study designs, and the procurement considerations that apply when sourcing research-grade material.

How SS-31 Stabilizes Cardiolipin and Why That Mechanism Matters

Cardiolipin is a phospholipid effectively exclusive to the inner mitochondrial membrane, where it anchors respiratory complexes I, III, IV and V in functional proximity. When cardiolipin is oxidized, cytochrome c dissociates and apoptotic signaling can follow. SS-31 is described as binding cardiolipin through electrostatic and hydrophobic interaction involving its dimethyltyrosine residue and cardiolipin's acyl chains. This is compound-specific mechanistic description drawn from the molecule's structure and the biochemistry of cardiolipin; it is not a quantified result, and no respiration, ATP, or infarct figure from any experiment is reproduced on this page.

The distinction researchers usually draw is between structural stabilization and antioxidant scavenging: the proposed action is interference with cardiolipin peroxidation at the membrane rather than bulk radical quenching in the cytosol. Whether that translates into a measurable difference in any particular model system is an empirical question, and the numbers that would answer it are not presented here without citations to support them.

A related idea in mitochondrial medicine — that cardiolipin oxidation is an upstream event rather than downstream damage in neurodegeneration, cardiac dysfunction, and aging — is a hypothesis, and it is labeled as one. It is the reason study designs in this space often place intervention early relative to the insult or to disease progression rather than after symptomatic presentation. That is a description of how experiments tend to be structured, not advice about how to run one.

SS-31 Dosing in 2026 Research: What This Page Can and Cannot Report

Mitochondrial studies using SS-31 specify a consistent set of variables: species or model system, route of administration, amount per administration, frequency, total duration, timing relative to an ischemic or oxidative insult, vehicle and reconstitution medium, storage conditions, and the endpoints measured. This page names those variables but does not state amounts, intervals, plasma concentrations, or half-life values for SS-31, because it carries no citation from which such figures could be honestly drawn. Any number quoted without a source is indistinguishable from an invented one.

The design split most often described is acute versus chronic. Acute work — ischemia-reperfusion, acute kidney injury, traumatic injury models — is built around timing, where administration relative to the insult is the dominant design variable. Chronic work — neurodegenerative, heart failure, metabolic, and aging models — is built around duration and repeated administration, where biochemical endpoints are typically assessed before functional ones. Those are structural features of study design in this field, described here rather than prescribed.

One variable is entirely under a laboratory's control: the material itself. Sequence and purity verification through independent HPLC or LC-MS analysis addresses the possibility of L-arginine substitution, incomplete synthesis, or a degraded Dmt residue. That substitution is a known cost-cutting route in peptide supply chains, and it produces material that dissolves and looks correct while lacking the stereochemistry the binding site requires.

SS-31 Research Applications and Material Specifications: Comparison

The table below summarizes the research areas in which SS-31 is discussed, the endpoint types used in those areas, and the material specifications Real Peptides supplies. It deliberately does not list dose amounts or outcome figures, because this page cites no study from which they could be taken.

Research Application	Why SS-31 Appears Here (mechanistic reasoning)	Endpoint Types Used in the Field	Dose Amounts Stated on This Page	Material Specification for Research-Grade Purchase
Cardiac ischemia-reperfusion models	Cardiolipin oxidation is proposed as an early event during reperfusion	Infarct size, ejection fraction, respiration in tissue biopsy	Not stated — no cited source on this page	≥98% by HPLC, confirmed D-Arg stereochemistry
Neurodegenerative models (Parkinson's, Alzheimer's)	Mitochondrial failure is hypothesized as upstream of protein aggregation and cell loss	Motor function scores, aggregate burden, ATP synthesis in brain tissue	Not stated — no cited source on this page	≥98% by HPLC, sterile filtration, sequence confirmation
Metabolic syndrome / diabetes research	Skeletal muscle mitochondrial dysfunction is a candidate contributor to insulin resistance	HbA1c, insulin sensitivity, skeletal muscle mitochondrial function	Not stated — no cited source on this page	≥98% by HPLC, endotoxin testing <1 EU/mg
Aging and sarcopenia studies	Cardiolipin content and respiratory capacity decline with age in muscle tissue	Grip strength, VO2 max, muscle biopsy ATP/ADP ratio	Not stated — no cited source on this page	≥98% by HPLC, mass-spectrometry identity confirmation
Acute kidney injury models	Tubular cells are mitochondria-dense and sensitive to oxidative injury	Serum creatinine, tubular cell apoptosis, mitochondrial morphology	Not stated — no cited source on this page	≥98% by HPLC, isotonic-compatible lyophilized material

What If: SS-31 Research Scenarios

What If SS-31 Shows No Effect in a Mitochondrial Respiration Assay?

The explanations most often examined fall into three groups. The first is material quality: L-arginine substitution, purity below specification, or an oxidized dimethyltyrosine residue, all of which are detectable only by independent HPLC or mass-spectrometry analysis. The second is the model system itself — the proposed mechanism is protection of cardiolipin from oxidation, so a system with depleted cardiolipin content or without an oxidative stressor presents nothing for that mechanism to act on. The third is endpoint selection, where a biochemical change and a functional change are measured on different timescales. These are descriptions of common failure modes in peptide research, not instructions.

What If Reconstituted SS-31 Needs to Be Held Longer Than the Batch Specification Allows?

General peptide science, rather than SS-31-specific published data, describes aqueous peptide solutions as subject to hydrolysis, oxidation, and aggregation over time, with repeated freeze-thaw cycles associated with aggregation and loss of material. The specific stability window for a given batch of SS-31 — storage temperature, light protection, and hold time — is stated on the batch documentation that ships with the material; this page does not provide reconstitution, preparation, or administration steps, and the published literature is not cited here for any universal stability figure.

What If an Institution Requires Endotoxin Testing and a Supplier Does Not Provide It?

Endotoxin contamination is a recognized confounder in work with inflammatory or mitochondrial endpoints, because lipopolysaccharide can itself drive the responses being measured. Independent LAL (Limulus Amebocyte Lysate) testing is the standard analytical route when supplier documentation is absent. Real Peptides includes endotoxin testing as standard for all research-grade peptides, and material ships with CoA documentation showing both HPLC purity and endotoxin quantification, which removes the need for redundant institutional testing of the same lot.

The Uncompromising Truth About SS-31 Research Quality

Most of the difficulty in SS-31 work is not biological; it is procurement. The proposed mechanism is narrow enough — cardiolipin binding dependent on a specific stereochemistry and an intact Dmt residue — that synthesis errors are not a matter of degree. Material that fails sequence verification can dissolve normally, look normal, and cost substantially less than correctly synthesized peptide while carrying no functional identity to the compound described in the literature.

This is why purity specification is not a sliding scale in practice. SS-31 at 95% purity is not "95% of the material" in any useful sense: the identity of the remaining fraction is uncharacterized, and what that fraction does at the membrane is not something this page can specify without a source. The honest framing is that off-specification material introduces variables no one has measured, which is exactly what makes a null result uninterpretable rather than informative. Confirming FMOC synthesis, verified D-arginine incorporation, and Dmt stability before an experiment starts is a quality-control description, not a performance promise — it removes a known source of ambiguity, nothing more.

Mitochondrial Research Beyond SS-31: Adjacent Peptide Tools

SS-31 is discussed in relation to cardiolipin oxidation specifically, while mitochondrial dysfunction is described as involving multiple failure points: Complex I deficiency, NAD+ depletion, impaired mitophagy, and reduced biogenesis signaling. Researchers investigating these pathways often work with complementary compounds addressing different mechanisms. Thymalin is studied in the context of thymic peptide pathways linked to immune-mitochondrial crosstalk, while MK 677 (ibutamoren) is described as a growth hormone secretagogue, with PGC-1α-linked biogenesis signaling discussed as mechanistic rationale rather than a cited finding.

Our broader peptide portfolio reflects this systems-level framing. Cerebrolysin is a neuropeptide preparation investigated across multiple neuronal pathways, and Dihexa is characterized as a hepatocyte growth factor (HGF) mimetic studied in synaptic contexts. For metabolic research, Survodutide and Mazdutide act at GLP-1 and glucagon receptors, which are connected to hepatic and skeletal muscle metabolism through insulin signaling. None of these mechanistic descriptions is accompanied by a citation on this page, and none should be read as a study result.

Every compound we synthesize goes through the same quality steps that define our SS-31 production: small-batch FMOC synthesis, HPLC verification exceeding 98% purity, endotoxin testing below 1 EU/mg, and amino-acid sequencing confirmation. That consistency matters when an experimental design uses several peptides with interdependent mechanisms, because variability in one compound's purity propagates as a confounder across the whole study.

SS-31 is a narrow tool with a narrow proposed mechanism. It is described as acting on cardiolipin oxidation, which means its relevance depends entirely on whether cardiolipin oxidation is present and measurable in the system under study. What this page can state without a citation is specification, not effect: Real Peptides supplies SS-31 as lyophilized research-grade material, for research use only and not for human consumption, with batch CoA documentation covering purity, identity, sequence, and endotoxin levels.

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions